business
J&J Is Focused on Fighting Cancer, Not Obesity Drugs, CEO Says
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are
Read full story on Bloomberg Markets → More top storiesAlso covered by
Euronews
How is the EU fighting illicit drugs? Ask the Euronews AI chatbot
Healthline
GLP-1 Drugs May Improve Breast Cancer Survival, Lower Risk of Recurrence
STAT News
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
Le Monde (English)
Anti-obesity centers prepare for wave of new patients as two drugs are now covered by French health insurance
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop